At A Glance

illumina®

Who we are

As a global leader in DNA sequencing and microarray-based solutions, we are dedicated to improving human health by unlocking the power of the genome. Our technology is responsible for generating more than 90% of the world's sequencing data.[1]

Quick facts

$3.54 Billion USD (2019)
Annual revenue

>7,800
Number of employees

Francis deSouza
President & CEO

San Diego, California, USA
Headquarters

1998
Year founded

Who we serve

We serve customers in a broad range of research, clinical, and applied markets, including:

Oncology	Reproductive health	Genetic disease	Microbiology	Infectious disease	Agriculture	Molecular & cell biology

We enable the adoption of genomic solutions in settings such as:

Universities and academic research centers	Pharmaceutical companies	Genome centers	Biotechnology companies	Hospitals	Consumer genetics companies	Government agencies

Where we operate



United States
San Diego (Headquarters)
Foster City
Hayward
Baltimore
Madison

Brazil
São Paulo

United Kingdom
Cambridge

France
Évry

Germany
Berlin

Netherlands
Eindhoven

China
Beijing
Shanghai

Japan
Tokyo
Osaka

Singapore

Australia
Melbourne

South Korea
Seoul

Making breakthroughs possible

Illumina has developed one of the world's most comprehensive genomics portfolio of integrated systems, consumables, and analysis tools. With each technological breakthrough, we help scientists better understand genetic variation at all levels of complexity.

Sequencing systems

NovaSeq™ 6000

Production-level sequencer for any species, application, or scale of sequencing project, including genomes, exome, and transcriptomes.

NextSeq™ 1000/2000

Benchtop sequencer for genome sequencing, exome sequencing, transcriptome sequencing and cytogenomic and methylation array scanning.

MiSeq™

Benchtop sequencer for targeted and small-genome sequencing.

MiniSeq™

Benchtop sequencer for targeted DNA and targeted RNA sequencing.

NextSeq™ 550Dx*

Benchtop IVD sequencer for comprehensive cancer testing and NIPT, as well as clinical research applications, from targeted panels to exomes; cleared or approved in > 20 countries.

MiSeq™ Dx*

Benchtop IVD sequencer for targeted tumor profiling and genetic disease testing, as well as clinical research applications including amplicon sequencing; cleared or approved in > 20 countries.

Array scanners

iSeq™ 100

Benchtop sequencer for targeted gene sequencing, direct amplicon sequencing, and small-genome sequencing.

iScan™ System

Genotyping, CNV analysis, DNA methylation, and gene expression profiling.

Cost of sequencing, per human whole genome



Since 2001, the cost of DNA sequencing has dropped more than 100,000x from $100 million per human genome to less than $600 today. Discoveries that were unimaginable a few years ago are now becoming routine.

Notable awards

2020 Bloomberg Gender-Equality Index

MEMBER OF Dow Jones Sustainability Indices In collaboration with SAM

America's Most JUST Companies Forbes 2020

Fortune Change the World 2019

Human Rights Campaign Foundation BEST PLACES TO WORK 2020 for LGBTQ Equality 100% CORPORATE EQUALITY INDEX

Glassdoor Employees' Choice Best Place to Work (2019)

Forbes' World's Best Employers (2019)

Forbes' The World's Most Innovation Companies (2018)

Computerworld Best Places to Work in IT (2018)

Forbes' America's Best Midsize Employers (2018)

*For *In Vitro* Diagnostic Use.

For Research Use Only (except as specifically noted). Not for use in diagnostic procedures.

References
1. Data calculations on file. Illumina, Inc., 2017
2. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at: www.genome.gov/sequencingcosts
3. NovaSeq™ 6000 Sequencing System

illumina®